Nautilus Biotechnology Inc (NAUT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $295.50M
Last updated: Nov 17, 2026 at 11:06 AM ET
Nautilus Biotechnology Inc (NAUT) Earnings: Report Dates and Results
Nautilus Biotechnology (NAUT) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Nautilus Biotechnology reported EPS of -$0.12, above the -$0.14 estimate. It beat the EPS estimate in each of the last 11 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NAUT has an expected report date of Feb 24, 2027.
NAUT Earnings Call
The latest NAUT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 23 quarters below that had an estimate, NAUT beat 18, missed 3 and matched 2. The widest gap in the table came in the quarter ended Mar 31, 2021, when EPS landed 337.50% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.12 | -$0.14 | -$0.15 - -$0.14 | +14.29% | Beat | N/A | 4 | 0 up, 1 down | Oct 27, 2026 | $234000 |
| Jun 30, 2026 | -$0.11 | -$0.14 | -$0.14 - -$0.14 | +21.43% | Beat | N/A | 1 | 0 up, 0 down | Jul 28, 2026 | $190000 |
| Mar 31, 2026 | -$0.12 | -$0.14 | -$0.15 - -$0.14 | +14.29% | Beat | N/A | 2 | 1 up, 0 down | Apr 28, 2026 | N/A |
| Dec 31, 2025 | -$0.11 | -$0.16 | N/A | +29.03% | Beat | N/A | 2 | 0 up, 0 down | Feb 26, 2026 | N/A |
| Sep 30, 2025 | -$0.11 | -$0.15 | -$0.16 - -$0.14 | +26.67% | Beat | N/A | 2 | 2 up, 0 down | Oct 27, 2025 | N/A |
| Jun 30, 2025 | -$0.12 | -$0.14 | N/A | +14.29% | Beat | N/A | N/A | 0 up, 0 down | Jul 31, 2025 | N/A |
| Mar 31, 2025 | -$0.13 | -$0.14 | -$0.14 - -$0.13 | +7.14% | Beat | N/A | 3 | 3 up, 0 down | Apr 29, 2025 | N/A |
| Dec 31, 2024 | -$0.14 | -$0.15 | -$0.18 - -$0.15 | +6.67% | Beat | N/A | 3 | 1 up, 0 down | Feb 26, 2025 | $9.60M |
| Sep 30, 2024 | -$0.13 | -$0.17 | -$0.18 - -$0.15 | +23.53% | Beat | N/A | 4 | 0 up, 0 down | Oct 29, 2024 | N/A |
| Jun 30, 2024 | -$0.14 | -$0.16 | -$0.18 - -$0.15 | +12.50% | Beat | N/A | 5 | 0 up, 0 down | Jul 30, 2024 | N/A |
| Mar 31, 2024 | -$0.15 | -$0.16 | -$0.18 - -$0.14 | +6.25% | Beat | N/A | 4 | 0 up, 0 down | Apr 30, 2024 | N/A |
| Dec 31, 2023 | -$0.14 | -$0.14 | -$0.19 - -$0.12 | 0.00% | In line | N/A | 4 | 0 up, 0 down | Feb 28, 2024 | $8.21M |
| Sep 30, 2023 | -$0.13 | -$0.16 | -$0.18 - -$0.15 | +18.75% | Beat | N/A | 4 | 0 up, 0 down | Oct 31, 2023 | N/A |
| Jun 30, 2023 | -$0.13 | -$0.16 | -$0.17 - -$0.12 | +18.75% | Beat | N/A | 4 | 0 up, 0 down | Aug 2, 2023 | N/A |
| Mar 31, 2023 | -$0.12 | -$0.17 | -$0.18 - -$0.16 | +29.41% | Beat | N/A | 3 | 0 up, 0 down | May 2, 2023 | N/A |
| Dec 31, 2022 | -$0.11 | -$0.15 | -$0.17 - -$0.13 | +26.67% | Beat | N/A | 3 | 0 up, 0 down | Feb 23, 2023 | N/A |
| Sep 30, 2022 | -$0.11 | -$0.15 | -$0.16 - -$0.14 | +26.67% | Beat | N/A | 4 | 1 up, 0 down | Nov 1, 2022 | N/A |
| Jun 30, 2022 | -$0.12 | -$0.17 | -$0.18 - -$0.15 | +29.41% | Beat | N/A | 4 | 0 up, 0 down | Aug 2, 2022 | N/A |
| Mar 31, 2022 | -$0.13 | -$0.16 | -$0.17 - -$0.15 | +18.75% | Beat | N/A | 3 | 0 up, 0 down | May 3, 2022 | N/A |
| Dec 31, 2021 | -$0.13 | -$0.13 | -$0.16 - -$0.11 | 0.00% | In line | N/A | 4 | 0 up, 0 down | Feb 24, 2022 | N/A |
| Sep 30, 2021 | -$0.12 | -$0.10 | -$0.11 - -$0.09 | -20.00% | Miss | N/A | 2 | 0 up, 0 down | Nov 2, 2021 | N/A |
| Jun 30, 2021 | -$0.19 | -$0.07 | -$0.09 - -$0.05 | -171.43% | Miss | N/A | 2 | N/A | Aug 10, 2021 | N/A |
| Mar 31, 2021 | -$0.35 | -$0.08 | N/A | -337.50% | Miss | N/A | N/A | N/A | Jun 10, 2021 | N/A |
| Dec 31, 2020 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2021 | N/A |
| Sep 30, 2020 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 13, 2020 | N/A |
| Jun 30, 2020 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Sep 18, 2020 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.47, after -$0.56 the year before. It was -$0.03 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.47 | N/A |
| Dec 31, 2024 | -$0.56 | N/A |
| Dec 31, 2023 | -$0.52 | N/A |
| Dec 31, 2022 | -$0.47 | N/A |
| Dec 31, 2021 | -$0.79 | N/A |
| Dec 31, 2020 | -$0.03 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,400 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,365 | 9 | |
| 2026Q2 | Jun 30, 2026 | 6,327 | 7 | |
| 2026Q1 | Mar 31, 2026 | 3,666 | 7 | |
| 2025Q4 | Dec 31, 2025 | 4,007 | 7 | |
| 2025Q3 | Sep 30, 2025 | 2,890 | 6 | |
| 2025Q2 | Jun 30, 2025 | 4,954 | 7 | |
| 2025Q1 | Mar 31, 2025 | 5,055 | 8 | |
| 2024Q4 | Dec 31, 2024 | 4,381 | 9 |
2026Q3 Earnings Call
Opening remarks
Marissa Moderator Thank you. Earlier today, Nautilus released financial results for the quarter ended September 30, 2026. If you haven't received this news release, or if you'd like to be added to the company's distribution list, please send an email to investorrelations@nautilus.bio. Joining me today from Nautilus are Sujal Patel, co-founder and CEO, Parag Mallick, co-founder and Chief Scientist, and Anna Mowry, Chief Financial Officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in the press release Nautilus issued today. Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast on October 27, 2026. With that, I'll turn the call over to Sujal.
Sujal Patel Co-founder and CEO Thanks, Marissa, and thank you all for joining us today. Last quarter, I walked you through a deliberate decision to concentrate our resources on proteoforms. This quarter, I want to talk to you about what proteoforms are, why we believe they're one of the most important opportunities in life sciences, and how we're building the foundation for meaningful long-term growth. Let me start with the idea that guides everything we do. We are making functional biology measurable. For decades, proteomics has primarily been about telling us how much protein is present. While the quantity of a protein is meaningful information, it's not the whole story. Most of today's tools don't have the resolution and scale required to measure the myriad of function-driving modifications that vary across every protein molecule. Shotgun mass spectrometry breaks proteins into peptides and infers the proteins from those pieces. Most affinity assays estimate average abundances by measuring a singular epitope on a protein. Either way, functionally distinct protein molecules are undifferentiated, as the information about splice variants, truncations, and which modifications co-occur on the same molecule is lost. That matters because the complexity of human biology does not come from the number of genes we carry. Consider the banana. A banana has almost 40,000 protein-coding genes. As humans, we are clearly more complex than a banana. In the early days of the Human Genome Project, scientists expected humans to have well over 100,000 genes. In fact, we only have about 20,000 genes, half as many as a banana.
Frequently Asked Questions About NAUT
When is Nautilus Biotechnology's next earnings date?
Nautilus Biotechnology's next earnings report is expected for Feb 24, 2027.
Did NAUT beat earnings estimates last quarter?
Yes. Nautilus Biotechnology reported EPS of -$0.12 for the quarter ended Sep 30, 2026, above the -$0.14 estimate, a 14.29% surprise.
What EPS do analysts expect from NAUT next quarter?
The consensus EPS estimate for Nautilus Biotechnology for the quarter ending Dec 31, 2026 is -$0.14 from 6 analysts, with estimates from -$0.15 to -$0.11.
How often does NAUT beat earnings estimates?
Nautilus Biotechnology beat the EPS estimate in each of the last 11 quarters, with an average surprise of +16.01%.
NAUT pages: Overview, Earnings, Forecast, Financials, Competitors